Related Experiment Video

Updated: Jun 23, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Management and therapy of chronic hepatitis C in HIV

Vincent Soriano1, Eugenia Vispo, Luz Martin-Carbonero

  • 1aDepartment of Infectious Diseases, Spain bHepatology Unit, CIBEREHD, Hospital Carlos III, Madrid, Spain.

Current Opinion in HIV and AIDS
|April 18, 2009
PubMed

Insights

Treating chronic hepatitis C in HIV-coinfected individuals requires tailored pegylated interferon and ribavirin therapy. Early virological response guides treatment duration, prioritizing antiretroviral therapy for those with low CD4 counts.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • HIV/AIDS Research

Background:

  • Chronic hepatitis C is a major cause of mortality and hospitalization in HIV-positive individuals.
  • Hepatitis C virus (HCV)/HIV coinfection presents unique treatment challenges, including reduced efficacy and increased side effects.

Purpose of the Study:

  • To review current treatment strategies for chronic hepatitis C in HIV-coinfected patients.
  • To outline optimal therapeutic approaches, considering patient-specific factors and potential drug interactions.

Main Methods:

  • Review of current treatment guidelines and clinical evidence for HCV/HIV coinfection.
  • Analysis of treatment efficacy, side effect profiles, and drug-drug interactions.

Main Results:

  • Pegylated interferon plus ribavirin is the recommended treatment, initiated without unnecessary prerequisites like liver biopsy.
  • Treatment continuation should be based on early virological response at weeks 4 and 12.
  • Standard ribavirin doses (1000-1200 mg/day) for at least 12 months are crucial; shorter durations (24 weeks) may be suitable for specific genotypes (2 and 3) with rapid virological response.
  • Patients with low CD4 percentages should prioritize highly active antiretroviral therapy (HAART).
  • Specific antiretroviral drugs (didanosine, zidovudine, stavudine, abacavir) have significant interactions with ribavirin and should be avoided or replaced when possible.

Conclusions:

  • Tailoring hepatitis C treatment to individual patient characteristics is essential for achieving optimal outcomes in coinfected individuals.
  • Managing HCV/HIV coinfection requires careful consideration of virological response, CD4 count, and potential drug interactions.
Abstract

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...